Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management

Rhea-AI Filing Summary

Immix Biopharma, Inc. is reported to have a significant shareholder group led by Eventide Asset Management, LLC. As of June 30, 2026, Eventide, as investment adviser to the Eventide Healthcare & Life Sciences Fund, is the beneficial owner of 3,891,019 shares of Immix Biopharma common stock, representing 5.6% of the outstanding common stock. Eventide holds sole voting and dispositive power over these shares, while individuals Finny Kuruvilla, M.D., Ph.D. and Robin C. John each report shared voting and dispositive power over the same 3,891,019 shares. The three parties have agreed to act as joint reporting persons regarding this ownership.

Key Figures

Shares beneficially owned: 3,891,019 shares Ownership percentage: 5.6% Sole voting power: 3,891,019 shares +2 more

5 metrics

Shares beneficially owned 3,891,019 shares Common stock beneficially owned by each reporting person as of June 30, 2026

Ownership percentage 5.6% Portion of Immix Biopharma outstanding common stock held by each reporting person

Sole voting power 3,891,019 shares Shares over which Eventide has sole power to vote or direct the vote

Shared voting power 3,891,019 shares Shares over which Kuruvilla and John each have shared voting power

Reporting date June 30, 2026 Date as of which ownership of 3,891,019 shares and 5.6% stake is reported

Key Terms

beneficial owner, sole voting power, shared dispositive power, Schedule 13G, +1 more

5 terms

beneficial owner financial

"is the beneficial owner of 3,891,019 shares of the Issuer's Common Stock"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

sole voting power financial

"Sole Voting Power 3,891,019.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"Shared Dispositive Power 3,891,019.00"

Schedule 13G regulatory

"to file a Statement on relating to their ownership of the Common Stock"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Rule 13d-1(k)(1) regulatory

"in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act"

FAQ

How large is Eventide Asset Management LLC’s stake in Immix Biopharma (IMMX)?

Eventide Asset Management, LLC beneficially owns 3,891,019 shares of Immix Biopharma common stock, representing 5.6% of the company’s outstanding common stock as of June 30, 2026, through the Eventide Healthcare & Life Sciences Fund.

Who are the reporting persons in the Immix Biopharma (IMMX) Schedule 13G?

The reporting persons are Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John. They have agreed to a joint reporting arrangement regarding their beneficial ownership of Immix Biopharma common stock.

What voting and dispositive powers does Eventide have over Immix Biopharma (IMMX) shares?

Eventide has sole voting power and sole dispositive power over 3,891,019 shares of Immix Biopharma common stock. Kuruvilla and John each report shared voting and shared dispositive power over the same shares.

Which fund holds Immix Biopharma (IMMX) shares managed by Eventide?

The Eventide Healthcare & Life Sciences Fund, a registered investment company advised by Eventide Asset Management, held 3,891,019 shares of Immix Biopharma common stock, representing 5.6% of the issuer’s outstanding common stock as of June 30, 2026.

What percentage of Immix Biopharma (IMMX) does each reporting person claim?

Each of Eventide Asset Management, Finny Kuruvilla, M.D., Ph.D., and Robin C. John reports beneficial ownership of 5.6% of Immix Biopharma’s outstanding common stock, corresponding to 3,891,019 shares each, reported as of June 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 11:37 AM Accepted by SEC EDGAR 08/14/2026 - 11:36 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Immix Biopharma, Inc.

(Name of Issuer)

Common stock, $0.0001 par value

(Title of Class of Securities)

45258H106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45258H106

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,891,019.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,891,019.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,891,019.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 45258H106

1

Names of Reporting Persons

Finny Kuruvilla, M.D. Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,891,019.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,891,019.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,891,019.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 45258H106

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,891,019.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,891,019.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,891,019.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Immix Biopharma, Inc.
(b)	Address of issuer's principal executive offices: 11400 West Olympic Blvd, Suite 200, Los Angeles, CA 90064
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Common stock, $0.0001 par value
(e)	CUSIP Number(s): 45258H106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 3,891,019 (ii) Kuruvilla: 3,891,019 (iii) John: 3,891,019
(b)	Percent of class: (i) Eventide: 5.6% (ii) Kuruvilla: 5.6% (iii) John: 5.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 3,891,019 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 3,891,019 (3) John: 3,891,019
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 3,891,019 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 3,891,019 (3) John: 3,891,019
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. As of June 30, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 3,891,019 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund which is a registered investment company. As of June 30, 2026, the Eventide Healthcare & Life Sciences Fund held 3,891,019 shares of the Issuer's Common Stock, representing 5.6% of the Issuer's outstanding Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	08/14/2026

Finny Kuruvilla, M.D. Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	08/14/2026

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	08/14/2026

Exhibit Information

EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: August 14, 2026 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title: General Counsel Date: August 14, 2026 Finny Kuruvilla, M.D., Ph. D. By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Date: August 14, 2026 Robin C. John By: /s/ Robin C. John Name: Robin C. John